[Skip to Content]
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
Purchase Options:
[Skip to Content Landing]
Views 607
Citations 0
February 20, 2018

Omitted Conflict of Interest Disclosures

JAMA. 2018;319(7):724. doi:10.1001/jama.2018.0613

In the Original Investigation entitled “Chemical Composition and Labeling of Substances Marketed as Selective Androgen Receptor Modulators and Sold via the Internet,”1 published in the November 28, 2017, issue of JAMA, there were omissions in the Conflict of Interest Disclosures section. The following disclosures should have been included: “Dr Bhasin reported receiving research grants from the National Institute of Diabetes and Digestive and Kidney Diseases, the National Institute of Child Health and Human Development, the National Institute on Aging, the National Institute of Nursing Research, Abbott, Ligand, Transition Therapeutics, Regeneron, Novartis, Althea, Biosensics, and Merck; receiving consulting fees from Sanofi and Regeneron; serving as the chair of the Endocrine Society’s expert panel that developed guideline for testosterone therapy of androgen deficiency in men; and serving on the American Board of Internal Medicine Endocrinology Board’s examination writing committee from 2006 to 2015 and as this committee’s chair from 2011 to 2015.” This article was corrected online.

Van Wagoner  RM, Eichner  A, Bhasin  S, Deuster  PA, Eichner  D.  Chemical composition and labeling of substances marketed as selective androgen receptor modulators and sold via the internet.  JAMA. 2017;318(20):2004-2010.PubMedGoogle ScholarCrossref